Abstract:Activation-induced cytidine deaminase (AID) initiates antibody diversification by mutating immunoglobulin loci in B lymphocytes. AID and related APOBEC3 (A3) enzymes also induce genome-wide mutations and lesions implicated in tumorigenesis and tumor progression. The most prevalent mutation signatures across diverse tumor genomes are attributable to the mistargeted mutagenic activities of AID/A3s. Thus, inhibiting AID/A3s has been suggested to be of therapeutic benefit. We previously used a computational-biochemical approach to gain insight into the structure of AID's catalytic pocket, which resulted in the discovery of a novel type of regulatory catalytic pocket closure that regulates AID/A3s that we termed the "Schrodinger's CATalytic pocket". Our findings were subsequently confirmed by direct structural studies. Here, we describe our search for small molecules that target the catalytic pocket of AID. We identified small molecules that inhibit purified AID, AID in cell extracts, and endogenous AID of lymphoma cells. Analogue expansion yielded derivatives with improved potencies. These were found to also inhibit A3A and A3B, the two most tumorigenic siblings of AID. Two compounds exhibit low micromolar IC50 inhibition of AID and A3A, exhibiting the strongest potency for A3A. Docking suggests key interactions between their warheads and residues lining the catalytic pockets of AID, A3A, and A3B and between the tails and DNA-interacting residues on the surface proximal to the catalytic pocket opening. Accordingly, mutants of these residues decreased inhibition potency. The chemistry and abundance of key stabilizing interactions between the small molecules and residues within and immediately outside the catalytic pockets are promising for therapeutic development.This article has not yet been cited by other publications.

Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using De Novo Drug Design Approach

Discovering Novel Chemical Inhibitors of Human Cyclophilin A: Virtual Screening, Synthesis, and Bioassay

Discovery of a Potent Peptidic Cyclophilin A Inhibitor Trp-Gly-Pro

Refinement and 3D‐QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker

Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction

Identification of potent CypD inhibitors via pharmacophore based virtual screening, docking and molecular dynamics simulation

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Accelerating Factor Xa Inhibitor Discovery with a De Novo Drug Design Pipeline

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Discovery of Cyanopyridine Scaffold As Novel Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors Through Virtual Screening and Preliminary Hit Optimisation.

One Novel Quinoxaline Derivative As a Potent Human Cyclophilin A Inhibitor Shows Highly Inhibitory Activity Against Mouse Spleen Cell Proliferation

Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization

De Novo Design of High Potent Dpp-Iv Inhibitors Based on the Scaffold of Cyanopyrrolidine

Structure‐Based Design of Ultrapotent Tricyclic Ligands for FK506‐Binding proteins

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

De novo design of drug-binding proteins with predictable binding energy and specificity

LigBuilder V3: A Multi-Target De Novo Drug Design Approach.

Drug design from the cryptic inhibitor envelope

Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B